Plain-English translation of NCT07217678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new treatment called Durysta—a single injection placed inside the eye—to see if it can lower eye pressure while reducing the need for daily glaucoma drops. Because people with glaucoma often use multiple eye drops every day, those drops can irritate and inflame the eye surface over time. Researchers want to know if this injection can control eye pressure while reducing that irritation.
Daily glaucoma medications are effective at lowering eye pressure and preventing vision loss, but the preservatives and frequent application can damage the delicate surface of the eye. This trial exists to find out whether the medication can help patients reduce their reliance on daily drops and experience less eye surface inflammation as a result.
You likely qualify if…
You likely don't qualify if…
You would receive a single injection of the medication directly into your eye during a visit at the University of Miami. After that, researchers would monitor your eye pressure, eye surface health, and inflammation levels over time to see whether the injection reduces your need for daily drops while decreasing eye surface damage. The study involves about 20 participants total, and your main commitment would be attending follow-up visits to have your eyes examined and tested.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Miami
Collaborators
AbbVie
Enrollment target
~20 participants
Started
February 2026
Primary completion
January 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Javier Paredes, BA, MBA
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.